STRATA SKIN SCIENCES, INC. Financials STRATA Skin Sciences, Inc.
Equities
SSKN
US86272A2069
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.5145 USD | -2.78% |
|
-5.60% | -6.47% |
| Apr. 09 | STRATA Skin Sciences, Inc. Announces Renewal of Exclusive Distribution Agreements in China and Japan | CI |
| Mar. 28 | Top Premarket Decliners | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 70.07 | 50.65 | 50.34 | 27.43 | 19.28 | 18.04 | - |
| Enterprise Value (EV) 1 | 70.07 | 50.65 | 50.34 | 27.43 | 19.28 | 18.04 | 18.04 |
| P/E ratio | -18.9 x | -11.5 x | -18.3 x | -4.94 x | -1.77 x | -2.45 x | -3.55 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 2.22 x | 2.19 x | 1.68 x | 0.76 x | 0.58 x | 0.57 x | 0.52 x |
| EV / Revenue | 2.22 x | 2.19 x | 1.68 x | 0.76 x | 0.58 x | 0.57 x | 0.52 x |
| EV / EBITDA | 50.2 x | -359 x | -286 x | 10.7 x | 20.1 x | 10.4 x | 4.17 x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 33,686 | 33,770 | 34,365 | 34,723 | 35,049 | 35,061 | - |
| Reference price 2 | 2.080 | 1.500 | 1.465 | 0.7901 | 0.5501 | 0.5145 | 0.5145 |
| Announcement Date | 3/17/20 | 3/24/21 | 3/21/22 | 3/31/23 | 3/27/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 31.59 | 23.09 | 29.98 | 36.16 | 33.36 | 31.79 | 34.77 |
| EBITDA 1 | 1.397 | -0.141 | -0.176 | 2.557 | 0.957 | 1.738 | 4.326 |
| EBIT 1 | -3.01 | -4.076 | -4.402 | -4.649 | -6.32 | -5.772 | -3.794 |
| Operating Margin | -9.53% | -17.65% | -14.68% | -12.86% | -18.95% | -18.16% | -10.91% |
| Earnings before Tax (EBT) 1 | -3.939 | -4.137 | -2.672 | -5.486 | -10.92 | -7.472 | -5.144 |
| Net income 1 | -3.597 | -4.394 | -2.706 | -5.549 | -10.83 | -7.572 | -5.244 |
| Net margin | -11.39% | -19.03% | -9.03% | -15.35% | -32.47% | -23.82% | -15.08% |
| EPS 2 | -0.1100 | -0.1300 | -0.0800 | -0.1600 | -0.3100 | -0.2100 | -0.1450 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 3/17/20 | 3/24/21 | 3/21/22 | 3/31/23 | 3/27/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 7.711 | 9.057 | 7.041 | 9.105 | 9.413 | 10.6 | 7.567 | 8.25 | 8.852 | 8.7 | 6.911 | 7.618 | 8.514 | 8.745 | 8.11 |
| EBITDA 1 | 0.615 | 0.581 | -0.508 | 0.207 | 1.064 | 1.794 | -0.759 | -0.095 | 1.291 | 0.52 | -0.0015 | 0.304 | 0.693 | 0.6385 | 0.35 |
| EBIT 1 | -0.465 | -0.622 | -2.303 | -1.694 | -0.786 | 0.134 | -2.586 | -1.962 | -0.615 | -1.157 | -1.832 | -1.536 | -1.167 | -1.242 | -1.48 |
| Operating Margin | -6.03% | -6.87% | -32.71% | -18.61% | -8.35% | 1.26% | -34.17% | -23.78% | -6.95% | -13.3% | -26.5% | -20.16% | -13.71% | -14.2% | -18.25% |
| Earnings before Tax (EBT) 1 | -0.517 | -0.827 | -2.502 | -1.892 | -0.995 | -0.097 | -2.835 | -3.148 | -1.053 | -3.886 | -2.256 | -1.961 | -1.592 | -1.666 | -1.88 |
| Net income 1 | -0.521 | -0.849 | -2.502 | -1.892 | -0.995 | -0.16 | -2.835 | -3.148 | -1.053 | -3.794 | -2.282 | -1.986 | -1.617 | -1.692 | -1.93 |
| Net margin | -6.76% | -9.37% | -35.53% | -20.78% | -10.57% | -1.51% | -37.47% | -38.16% | -11.9% | -43.61% | -33.01% | -26.07% | -18.99% | -19.34% | -23.8% |
| EPS 2 | -0.0200 | -0.0200 | -0.0700 | -0.0500 | -0.0300 | - | -0.0800 | -0.0900 | -0.0300 | -0.1100 | -0.0650 | -0.0550 | -0.0450 | -0.0500 | -0.0500 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/10/21 | 3/21/22 | 5/11/22 | 8/10/22 | 11/9/22 | 3/31/23 | 5/15/23 | 8/9/23 | 11/14/23 | 3/27/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | 0.12 | - | - | 3.55 | - | 0.6 | 0.7 |
| Capex / Sales | 0.36% | - | - | 9.82% | - | 1.89% | 2.01% |
| Announcement Date | 3/17/20 | 3/24/21 | 3/21/22 | 3/31/23 | 3/27/24 | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.5145
USD
Average target price
2.3
USD
Spread / Average Target
+347.04%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.47% | 18.04M | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +0.65% | 63.06B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B |
- Stock Market
- Equities
- SSKN Stock
- Financials STRATA Skin Sciences, Inc.
